Q3 2024 Alkermes Plc Earnings Call Transcript
Key Points
- Alkermes PLC (ALKS) reported strong growth in its proprietary product portfolio, with net sales reaching $273 million, reflecting an 18% year-over-year increase.
- Vivitrol net sales grew by 14% year-over-year, driven by demand in the alcohol dependence indication, with expectations to reach the high end of the $410-$430 million range for the full year.
- Lybalvi showed significant growth with net sales of $74.7 million, a 37% year-over-year increase, supported by strong demand and expanded prescriber reach.
- The company is in a strong financial position with $927.8 million in cash and investments, and has repurchased 4.4 million shares as part of a $400 million share repurchase program.
- Alkermes PLC (ALKS) is advancing its ALKS 2680 clinical program with positive phase 1B data, and phase 2 studies are underway, expected to be a transformative catalyst for the company.
- The Aristada product family experienced softness in the schizophrenia long-acting antipsychotic market, with expectations for net sales to be at the lower end of the $340-$360 million range.
- Manufacturing and royalty revenues decreased, with a notable drop in revenues from long-acting Invega products, impacting overall financial performance.
- The company anticipates a significant impact on royalty and manufacturing revenues in 2025, with a projected decrease of approximately $200 million due to the conclusion of certain royalties and manufacturing transitions.
- Operating expenses are expected to increase modestly in 2025, driven by investments in the ALKS 2680 program and expansion of the psychiatry commercial footprint.
- Alkermes PLC (ALKS) faces competitive dynamics in the antipsychotic space, requiring increased investment in personal promotion to maintain market share.
Greetings and welcome to the Alkermes third quarter, 2024 financial results conference call.
My name is Maria and I'll be your operator for today's call.
(Operator Instructions)
I will now turn the call over to Sandra Combs, Senior Vice President of Investor Relations and Corporate Affairs.
Sandy. You may now begin.
Good morning. Welcome to the Alkermes PLC conference call to discuss our financial results and business update for the quarter ended September 30th 2024 with me today are Richard Pops, our CEO Todd Nichols, our Chief Commercial Officer and Blair Jackson, our Chief Operating Officer.
During today's call, we will be referencing slides these slides along with our press release related financial tables and reconciliations of the GAAP to non GAAP financial measures that we'll discuss today are available on the investor section of Alkermes.com. We believe the non GAAP financial measures in conjunction with the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
